Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab vs temozolomide with radiation in newly diagnosed MGMT-unmethylated glioblastoma
jRCT2080223083Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of nivolumab in glioblastoma (GBM) (2 arms), sponsored by Ono Pharmaceutical. Started Jan 2016; status: completed.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on jRCT2080223083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223083.